Dual Incretin Peptide (GLP-1 & GIP Agonist) | Weight Loss, Glycaemic Support & Metabolic Research | For Research Use Only

Tirzepatide is a groundbreaking dual-action peptide that activates both GLP-1 and GIP receptors, offering a potent combination for research focused on obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. It enhances insulin secretion, suppresses glucagon, and slows gastric emptying, contributing to effective appetite control and sustained fat loss.

The 20mg vial format is ideal for low-to-moderate dosing protocols or titration-based research designs.

🔍 Key Features

• Dual GLP-1 + GIP Receptor Agonism

• Appetite Suppression & Increased Satiety

• Improves Insulin Sensitivity & Blood Glucose Control

• Promotes Body Fat Reduction

• Supports Weekly Research Protocols

• Clinically Outperforms GLP-1 Monotherapies

⚙️ Compound Details

• Peptide Name: Tirzepatide

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₀N₆₀O₆₅

• Molecular Weight: ~4813.45 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 20mg per vial

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C in a dry, dark place

• Reconstitution: Add 1–2ml sterile bacteriostatic water

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Heat, direct sunlight, and repeated freeze-thaw cycles

⚠️ For Research Use Only

Tirzepatide – 20mg is intended solely for scientific research purposes. It is not for human consumption or clinical use.